trabectedin shows activity in some paediatric solid tumours

Inpharma 1479 - 19 Mar 2005

■ Trabectedin* [ecteinascidin-743] shows activity insome paediatric treatment-refractory solid tumours,reports a multinational team of researchers. Theirphase I study included 12 patients aged 2–16 yearswith treatment-refractory extracranial solid tumourswho received an IV infusion of trabectedin 1100 µg/m2

(n = 6) or 1300 µg/m2, every 21 days.** A completeresponse was observed for 10 months in one patientwith recurrent Ewing’s sarcoma and pulmonarymetastases; another patient with Ewing’s sarcoma andlung metastases exhibited stable disease but waswithdrawn after the second treatment course due toradiation-induced toxicity.* Ortho Biotech, PharmaMar; phase II for sarcoma in the US,Australia, Canada and Europe** This study was supported by PharmaMar, Spain.

Lau L, et al. A phase I and pharmacokinetic study of ecteinascidin-743(Yondelis) in children with refractory solid tumors: a children’s oncologygroup study. Clinical cancer research: an official journal of the AmericanAssociation for Cancer Research 11: 672-677, No. 2, Part 1, 15 Jan2005 800979824

1

Inpharma 19 Mar 2005 No. 14791173-8324/10/1479-0001/$14.95 Adis © 2010 Springer International Publishing AG. All rights reserved